- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06144918
Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of Two Concentrations of SBI-100 Ophthalmic Emulsion in Patients With Elevated Intraocular Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients with elevated pressure in the eye. Patients will be randomly given either:
- 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion
- 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion
- Placebo Ophthalmic Emulsion
Patients will be tested before starting and will have one drop of the product placed into each eye twice a day for 14 days, by the site and by the patient. At the end of the study, researchers will compare the groups to see if there is a change from before use of SBI-100 Ophthalmic Emulsion to the end of study.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91204
- Global Research Management, Inc.
-
Newport Beach, California, United States, 92663
- Eye Research Foundation
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Scott & Christie and Associates, PC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age or greater at time of informed consent.
- Diagnosis of either primary open angle glaucoma (POAG) or ocular hypertension (OHT) in each eye.
Intraocular Pressure (IOP) Criteria:
- If currently on an IOP-lowering therapy, patient is willing to withhold therapy according to study requirements, and in the opinion of the Investigator, can do so without significant risk.
- If treatment naïve, Screening IOP is ≥ 21 and ≤ 36 mmHg in each eye, and in the opinion of the Investigator, is likely to be controlled on a single IOP-lowering therapy.
- 08:00 Hour IOP is between 21 and 36 mmHg in each eye on Day-1 and Day 1.
- Central corneal thickness between 480 and 620 μm at Screening in each eye.
- Best correct visual acuity (BCVA) for distance equivalent to 20/100 or better in each eye at Screening and Day 1 (pre-dose).
Exclusion Criteria:
Either eye:
- Mean/Median intraocular pressure > 36 mmHg at Screening and/or any time prior to treatment administration.
- Concurrent treatment for glaucoma requiring more than 2 topical therapies (either as 2 independent monotherapies or as fixed dose combination), oral IOP-lowering therapy and/or in the opinion of the Investigator cannot be controlled on a single IOP therapy.
- Has planned ocular surgeries/procedures within the duration of the study.
Any occurrences of the following prior to Day 1:
- Ocular trauma or surgery within 6 months
- Ocular laser treatments within 3 months
- In the opinion of the Investigator history or evidence of clinically significant ocular inflammation, including but not limited to blepharitis, conjunctivitis, etc.
- History of recurrent ocular herpes (simplex or zoster)
- Previous glaucoma intraocular surgery or glaucoma laser procedure and/or refractive surgery (e.g., radial keratotomy, PRK, SLT, LASIK, etc.) within 6 months
- Ocular medication within 30 days prior, except for:
i. IOP-lowering therapies (washed-out per study requirements) ii. Lid scrubs iii. Artificial tears, gels and/or ointments to treat dry eye disease that in the opinion of the Investigator is not considered chronic use
- Visual field loss, in the opinion of the Investigator, is functionally significant
- Will require contact lenses and cannot refrain from using them at least 7 days prior to Day 1 and throughout the study.
General/Systemic:
- Participation in any investigational study within 30 days of screening.
- Known hypersensitivity or allergic reaction to cannabinoids, cannabis, sesame seed/oil or any component of the SBI-100 Ophthalmic Emulsion formulation and/or topical anesthetics.
- Females of childbearing potential (not confirmed as post-menopausal or surgically sterile within the 6 months prior to screening) who are pregnant, nursing, or planning a pregnancy during the study and not using a reliable method of contraception from screening until at least 30 days after the last dose.
- Males with partners of childbearing potential and do not agree to use a reliable method of contraception during the study and at least 30 days after the last dose.
- Patients with a history of substance or alcohol abuse, considered chronic tetrahydrocannabinol (THC) users and/or test positive for alcohol or illicit drug use at Screening or Day-1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBI-100 Ophthalmic Emulsion, 0.5%
All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
|
0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
|
Placebo Comparator: SBI-100 Ophthalmic Emulsion Placebo
All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
|
Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
|
Experimental: SBI-100 Ophthalmic Emulsion, 1%
All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
|
1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular hypotensive efficacy
Time Frame: baseline and day 14
|
To evaluate the diurnal ocular hypotensive efficacy of 2 dose levels of SBI-100 Ophthalmic Emulsion compared to placebo in patients with elevated Intraocular Pressure (IOP)
|
baseline and day 14
|
Ocular and systemic safety
Time Frame: baseline up to day 16
|
To evaluate the ocular and systemic safety of SBI-100 Ophthalmic Emulsion in patients with elevated IOP
|
baseline up to day 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular hypotensive efficacy at individual timepoints
Time Frame: baseline through day 14
|
To evaluate the ocular hypotensive efficacy at individual time points of SBI-100 Ophthalmic Emulsion in patients with elevated IOP
|
baseline through day 14
|
Application comfort
Time Frame: baseline up to day 16
|
To evaluate the application comfort of SBI-100 Ophthalmic Emulsion
|
baseline up to day 16
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Tu Diep, Skye Bioscience, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBI-100-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
Clinical Trials on SBI-100 Ophthalmic Emulsion, 0.5%
-
AllerganCompletedArthritis, Rheumatoid | Lupus Erythematosus, Systemic | Scleroderma, Systemic | Keratoconjunctivitis Sicca | Sjogren's SyndromeUnited States
-
AllerganCompletedDry Eye SyndromesUnited States
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedOcular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract SurgeryUnited States
-
Aldeyra Therapeutics, Inc.CompletedDry Eye SyndromesUnited States
-
Stuart Therapeutics, Inc.ORA, Inc.Completed
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Laboratorios PoenCompletedPrimary Open-angle GlaucomaArgentina
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed